|9.88||+0.2400||+2.49%||Vol 120.77K||1Y Perf 178.93%|
|Apr 20th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||10.33||Analyst Rating||Moderate Buy 2.00|
|Potential %||4.55||Finscreener Ranking||★★★★ 54.18|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★★★★ 56.13|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||★★ 45.09|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Market Cap||339.06M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||76.85||Earnings Date||12th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||12th May 2021|
|Estimated EPS Next Report||-0.15|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||111.09K|
|Avg. Monthly Volume||101.63K|
|Avg. Quarterly Volume||91.18K|
Apyx Medical Corporation (NASDAQ: APYX) stock closed at 9.88 per share at the end of the most recent trading day (a 2.49% change compared to the prior day closing price) with a volume of 120.77K shares and market capitalization of 339.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 266 people. Apyx Medical Corporation CEO is Charles D. Goodwin.
The one-year performance of Apyx Medical Corporation stock is 178.93%, while year-to-date (YTD) performance is 37.22%. APYX stock has a five-year performance of %. Its 52-week range is between 2.81 and 12.01, which gives APYX stock a 52-week price range ratio of 76.85%
Apyx Medical Corporation currently has a PE ratio of -26.80, a price-to-book (PB) ratio of 5.19, a price-to-sale (PS) ratio of 14.56, a price to cashflow ratio of 133.80, a PEG ratio of 2.32, a ROA of -14.30%, a ROC of -22.49% and a ROE of -16.84%. The company’s profit margin is -43.94%, its EBITDA margin is -66.70%, and its revenue ttm is $22.71 Million , which makes it $0.66 revenue per share.
Of the last four earnings reports from Apyx Medical Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Apyx Medical Corporation’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Apyx Medical Corporation is Moderate Buy (2), with a target price of $10.33, which is +4.55% compared to the current price. The earnings rating for Apyx Medical Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apyx Medical Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apyx Medical Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.80, ATR14 : 0.63, CCI20 : 6.34, Chaikin Money Flow : 0.03, MACD : -0.05, Money Flow Index : 46.51, ROC : -0.21, RSI : 59.94, STOCH (14,3) : 62.18, STOCH RSI : 0.43, UO : 53.36, Williams %R : -37.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apyx Medical Corporation in the last 12-months were: Charles D. Goodwin (Buy at a value of $93 197), Lawrence J. Waldman (Option Excercise at a value of $15 632), Michael Geraghty (Option Excercise at a value of $21 075)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.